Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Biochemical Manifestation of HIV Lipodystrophy Syndrome.

Ihenetu K, Mason D.

Int J MCH AIDS. 2012;1(1):92-101. Review.

2.

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B.

PLoS One. 2015 Oct 12;10(10):e0140358. doi: 10.1371/journal.pone.0140358. eCollection 2015.

3.

Epidemiology and management of antiretroviral-associated cardiovascular disease.

Chastain DB, Henderson H, Stover KR.

Open AIDS J. 2015 Mar 31;9:23-37. doi: 10.2174/1874613601509010023. eCollection 2015.

4.

The successful use of lipectomy in the management of airway obstruction in a woman with HIV-associated lipodystrophy.

Tsui E, Bogdasarian R, Blomain E.

BMJ Case Rep. 2015 Feb 18;2015. pii: bcr2014208053. doi: 10.1136/bcr-2014-208053.

5.

HIV-associated lipodystrophy: a review from a Brazilian perspective.

Alves MD, Brites C, Sprinz E.

Ther Clin Risk Manag. 2014 Jul 17;10:559-66. doi: 10.2147/TCRM.S35075. eCollection 2014. Review.

6.

In vitro and in vivo effects of IGF-I on adiposity in HIV-associated metabolic disease: a pilot study.

Kim RJ, Vaghani S, Zifchak LM, Quinn JH, He W, Tebas P, Frank I.

Arch Med Res. 2013 Jul;44(5):361-9. doi: 10.1016/j.arcmed.2013.06.001. Epub 2013 Jul 16.

7.

Lipid peroxidation and total cholesterol in HAART-naïve patients infected with circulating recombinant forms of human immunodeficiency virus type-1 in Cameroon.

Teto G, Kanmogne GD, Torimiro JN, Alemnji G, Nguemaim FN, Takou D, Nanfack A, Tazoacha A.

PLoS One. 2013 Jun 7;8(6):e65126. doi: 10.1371/journal.pone.0065126. Print 2013.

8.

Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.

Glesby MJ, Albu J, Chiu YL, Ham K, Engelson E, He Q, Muthukrishnan V, Ginsberg HN, Donovan D, Ernst J, Lesser M, Kotler DP.

PLoS One. 2013 Apr 12;8(4):e61160. doi: 10.1371/journal.pone.0061160. Print 2013.

9.

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK.

Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10.

10.

Rare adipose disorders (RADs) masquerading as obesity.

Herbst KL.

Acta Pharmacol Sin. 2012 Feb;33(2):155-72. doi: 10.1038/aps.2011.153. Review.

11.

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.

Bedimo R.

HIV AIDS (Auckl). 2011;3:69-79. doi: 10.2147/HIV.S14561. Epub 2011 Jul 10.

12.

Management of the metabolic effects of HIV and HIV drugs.

Brown TT, Glesby MJ.

Nat Rev Endocrinol. 2011 Sep 20;8(1):11-21. doi: 10.1038/nrendo.2011.151. Review.

13.

Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.

Troll JG.

Curr Atheroscler Rep. 2011 Feb;13(1):51-6. doi: 10.1007/s11883-010-0152-1. Review.

14.

Pathogenesis and treatment of HIV lipohypertrophy.

Leung VL, Glesby MJ.

Curr Opin Infect Dis. 2011 Feb;24(1):43-9. doi: 10.1097/QCO.0b013e3283420eef. Review.

15.

Lipodystrophy: pathophysiology and advances in treatment.

Fiorenza CG, Chou SH, Mantzoros CS.

Nat Rev Endocrinol. 2011 Mar;7(3):137-50. doi: 10.1038/nrendo.2010.199. Epub 2010 Nov 16. Review.

16.

Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.

Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK.

J Clin Endocrinol Metab. 2011 Jan;96(1):150-8. doi: 10.1210/jc.2010-1587. Epub 2010 Oct 13.

Supplemental Content

Support Center